RxDoctor Payments Data

Andrew Weber, MD

Pulmonary Disease · Bethpage, NYNPI 1356372544

Payments from drug & device makers

$4,648in general payments, 2019–2025

Across 235 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$971
  • Philips North America LLC$606
  • Boehringer Ingelheim$349
  • Actelion Pharmaceuticals US, Inc.$257
  • Electromed, Inc.$198
  • plus $655 from 15 others

What the payments were for

  • Food & beverage$4,51197%
  • Education$1373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,648 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$88,794
Medicare patients
124
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$68,003
MounjaroTirzepatide40$39,737
EliquisApixaban19$20,043
OzempicSemaglutide17$15,700
JardianceEmpagliflozin12$15,352
Breo ElliptaFluticasone/Vilanterol13$14,298
FarxigaDapagliflozin Propanediol15$13,150
XareltoRivaroxaban14$12,844
InvokanaCanagliflozin13$10,799
SymbicortBudesonide/Formoterol Fumarate14$3,219
Albuterol Sulfate HfaAlbuterol Sulfate71$3,145
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,929
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,698
Amlodipine Besylate107$1,150
Atorvastatin Calcium144$1,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,612$82,300101 claims
Johnson & JohnsonXarelto, Invokana$22$23,64327 claims
PfizerEliquis$29$20,04319 claims
AstraZenecaFarxiga, Symbicort$971$16,37029 claims
Boehringer IngelheimJardiance$349$15,35212 claims
AbbVieSynthroid$46$86616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Bethpage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →